Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption

PHASE3CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Intrahepatic Cholestasis Associated With Alcoholic Liver Disease
Interventions
DRUG

Ademetionine IV+tablet

IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks

DRUG

Ademetionine tablet

oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks

Trial Locations (12)

107014

Research facility ORG-000962, Moscow

117292

Research facility ORG-000957, Moscow

117630

Research facility ORG-000967, Saint Petersburg

119435

Research facility ORG-000961, Moscow

119992

Research facility ID ORG-000960, Moscow

125284

Research facility ID ORG-000726, Moscow

142190

Research facility ORG-000958, Troitsk

150003

Research facility ORG-000969, Yaroslavl

191015

Research facility ORG-000966, Saint Petersburg

195257

Research facility ORG-000968, Saint Petersburg

197022

Research facility ORG-000965, Saint Petersburg

198216

Research facility ORG-000970, Saint Petersburg

Sponsors

Lead Sponsor

Collaborators (3)

All Listed Sponsors
collaborator

Ascent

UNKNOWN

collaborator

Datamap

INDUSTRY

collaborator

ClinIntel

INDUSTRY

collaborator

Catalent

INDUSTRY

lead

Abbott

INDUSTRY

NCT02200029 - Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption | Biotech Hunter | Biotech Hunter